Dec. 3 at 5:01 PM
$XERS Why I’m truly not satisfied seeing Xeris under a
$3B MC(~
$20/share) at this stage
Xeris is having a phenomenal year in 2025, and it should realistically deliver an excellent Q4 as well.
The company is aiming to reach close to
$400M in revenue in 2026, while maintaining roughly 85% gross margins.
To put that into perspective -> that’s economically similar to generating
$800M in revenue at 43% gross margins.
Xeris is achieving this with best-in-class tech, multiple drugs(derisked), significant tech collaborations and contracts, one long-patent drug that is aiming blockbuster status, and one Phase 3 drug, potential multiple Blockbuster, with a very high likelihood to be commercial 2029.
All of that easily supports a
$3B valuation today in this sector, and potentially
$5B by 2026. However, markets sometimes need one more year of consistent execution, just as we’ve seen in recent years, to fully price in that value. So be that.
